Part 3/7:
Adding to this promising landscape, the deal has financial implications for Sangamo, offering them an initial investment of $150 million, potentially exceeding $3 billion in milestone payments tied to numerous future products. While investment opportunities abound, it's essential to note that Sangamo does not yet have clinical products ready for cancer treatment. Investors should temper enthusiasm until clearer data emerges from ongoing and upcoming trials.